RxDoctor Payments Data

Nong Chrang

Family · Somersworth, NHNPI 1043673379

Payments from drug & device makers

$1,333in general payments, 2019–2025

Across 63 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$555
  • AstraZeneca$146
  • Novo Nordisk$110
  • Daiichi Sankyo Inc.$81
  • Amgen$65
  • GSK$58
  • plus $318 from 8 others

What the payments were for

  • Food & beverage$1,333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,333 in reported general payments places this provider in the 85th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire

Medicare billing

Part B allowed, 2024
$81,797
Medicare patients
274
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$63,681
JardianceEmpagliflozin42$43,704
RybelsusSemaglutide27$33,130
OzempicSemaglutide31$32,232
Tresiba Flextouch U-200Insulin Degludec13$26,793
OxycontinOxycodone Hcl22$24,327
JanuviaSitagliptin Phosphate11$16,525
LinzessLinaclotide11$11,680
SymbicortBudesonide/Formoterol Fumarate31$10,195
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,410
Breo ElliptaFluticasone/Vilanterol13$5,210
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$4,858
Gabapentin243$4,409
Fenofibrate16$4,142
Atorvastatin Calcium502$4,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$110$65,36258 claims
PfizerEliquis$50$63,68156 claims
MerckJanuvia$46$16,52511 claims
GSKTrelegy Ellipta, Breo Ellipta$58$13,62026 claims
AbbVieLinzess$555$11,68011 claims
AstraZenecaSymbicort$146$10,19531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 713 family providers in New Hampshire.

Other family in Somersworth

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →